Sex Differences in the Treatment Effect of Targeted Heart Rate Aerobic Exercise in Adolescents with Acute Sport-Related Concussion.

J NeurotraumaMar 18, 2026 (epub)
Clinical ResearchPediatrics

Elizabeth V Castro, Haley M Chizuk, John J Leddy et al.

✦ AI-curated · Sources linked

In 30 seconds

This reanalysis of two randomized controlled trials examined whether sex modified recovery after targeted heart-rate aerobic exercise versus stretching in adolescents with acute sport-related concussion. Recovery times did not differ significantly between males and females overall. In sex-stratified analyses, males assigned aerobic exercise recovered 6 days faster than males assigned stretching in the first trial and 8 days faster in the second; corresponding 3-day differences among females were not statistically significant. The findings suggest a possible sex-related difference in treatment response, but the authors call for adequately powered studies.

Key findings

  • In the first trial, males assigned aerobic exercise recovered 6 days faster than those assigned stretching (p = 0.004).
  • In the second trial, males assigned aerobic exercise recovered 8 days faster than those assigned stretching (p = 0.020).
  • Among females, the 3-day recovery differences between aerobic exercise and stretching were not significant in either trial (p = 0.564 and p = 0.587).
  • Recovery times did not differ significantly between males and females in either trial, regardless of intervention.

Why it matters

The results raise the possibility that adolescent males and females may not respond identically to prescribed aerobic exercise after sport-related concussion. Recognising this potential variability is relevant when interpreting trial evidence and designing future studies, while the nonsignificant findings in females mean the apparent difference should not be treated as established.

What to keep in mind

This was a reanalysis of prior trials, and the authors state that future adequately powered studies are needed to account for variability between sexes.

Source

Published in J Neurotrauma. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.